环氧合酶抑制剂在肝癌预防和治疗中的研究进展  

Advancements of cyclooxygenase inhibitor in the prevention and treatment of hepatoma

作　　者：解新玉[1] 殷积彬[1] 吕志武[1] 齐兴四[1] 

机构地区：[1]哈尔滨医科大学附属第二医院消化内科,黑龙江省哈尔滨市150086

出　　处：《世界华人消化杂志》2009年第2期158-163,共6页World Chinese Journal of Digestology

基　　金：黑龙江省教育厅2007年科学技术研究项目;No.11521184~~

摘　　要：研究显示在许多肿瘤中,环氧合酶(COX)2及其产物过度表达.非甾体类抗炎药可以抑制环氧合酶的活性,从不同途径达到抑制肿瘤细胞的生长、诱导凋亡,抑制血管形成、降低肿瘤的侵袭力和转移性.肝癌是世界常见的恶性肿瘤之一,预后较差,形成机制尚未清楚,其预防和治疗水平有限.因此找到一种新的抗癌药物并研究其抗肝癌的作用机制,在肝癌的预防和治疗中有重要意义.本文对COX抑制剂与肝癌形成和肝癌的预防和治疗中进展作一综述.It was reported that the cyclooxygenase-2 （COX-2） and its products were over-expressed in many malignant tumors. Non-steroidal antiinflammatory drugs （NSAIDs） can inhibit COX activity, and also can reduce proliferation, enhance apoptosis, decrease angiogenesis and invasiveness of tumor cells. Hepatoma is one of common malignancies worldwide, and its prognosis is still extremely poor and the cellular mechanisms contributing to hepatic carcinogenesis are relatively unknown. Therefore, the prevention and treatment of liver cancer are limited. At present, it is important to find new drugs and investigate their action mechanisms. This article provides a brief review on the research progress of COX inhibitor in the prevention and treatment of hepatoma.

关 键 词：环氧合酶 抑制剂 肝癌 非甾体类抗炎药 肿瘤 

分 类 号：R735.7[医药卫生—肿瘤]